IPO Databook: Betta Pharmaceuticals (HK) - Aug 2026

105 Views30 Aug 2026 10:14

SUMMARY

Betta Pharmaceuticals is a key player in China's innovative drug industry, evolving into a fully integrated, commercial-stage biopharmaceutical company.
Icotinib sustained annual sales exceeding RMB1 billion for ten consecutive years since 2016, with over RMB18 billion cumulative sales.
Revenue was RMB3,609,338 thousand in 2025, and gross profit was RMB2,825,901 thousand for the same year.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream